Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

657124

	registered interest
	date	12/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Skin Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what restrictions have been placed on patients accessing treatments for advanced (stage 4) melanoma by (a) NHS England, (b) his Department and (c) NICE.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	57212
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The Department has placed no restrictions on patients accessing treatments for advanced (stage 4) melanoma.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published guidance on the following treatments for melanoma. National Health Service commissioners are legally required to fund drugs and treatments recommended by NICE for eligible patients within three months of final guidance.</p><p> </p><table><tbody><tr><td><p>Appraisal number</p></td><td><p>Year of publication</p></td><td><p>Technology/condition</p></td><td><p>Recommendation</p></td></tr><tr><td><p>TA268</p></td><td><p>2012</p></td><td><p>Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA269</p></td><td><p>2012</p></td><td><p>Vemurafenib for locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA319</p></td><td><p>2014</p></td><td><p>Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA321</p></td><td><p>2014</p></td><td><p>Dabrafenib for unresectable or metastatic BRAF V600 mutation‑positive melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA357<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma after disease progression with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA366<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma not previously treated with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA384</p></td><td><p>2016</p></td><td><p>Nivolumab for advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA396</p></td><td><p>2016</p></td><td><p>Trametinib in combination with dabrafenib for unresectable or metastatic melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA400</p></td><td><p>2016</p></td><td><p>Nivolumab in combination with ipilimumab for advanced melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA410</p></td><td><p>2016</p></td><td><p>Talimogene laherparepvec for unresectable metastatic melanoma</p></td><td><p>Optimised recommendation for talimogene laherparepvec as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if: - treatment with systemically administered immunotherapies is not suitable; and - the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.</p></td></tr><tr><td><p>TA414</p></td><td><p>2016</p></td><td><p>Cobimetinib in combination with vemurafenib for unresectable or metastatic BRAF V600 mutation-positive melanoma</p></td><td><p>At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.</p></td></tr></tbody></table><p><sup>1</sup> pembrolizumab within its licensed indication was appraised across two separate appraisals.</p><p> </p><p>NHS England has advised that it has carefully translated the evidence base on which NICE has based its recommendations of clinical and cost effectiveness into practical clarifications which directly relate to how the recommended drug indication is incorporated into known treatment pathways in use in England.</p><p> </p><p>Each set of clarifications is in keeping with the NICE recommendations within the marketing authorisation of the relevant drug.</p><p> </p><p>The treatment criteria for both Cancer Drugs Fund and baseline-funded drug indications are set out in the National Cancer Drugs Fund List which is available at:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf</a></p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 57299 question first answered 20/12/2016 10:28:45 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4025 label Biography information for Mrs Pauline Latham

657941

	registered interest
	date	13/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments: Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to prevent NHS England from imposing restrictions on patients' access to NICE-approved treatments for melanoma and other conditions; and if he will make a statement.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	57299
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The Department has placed no restrictions on patients accessing treatments for advanced (stage 4) melanoma.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published guidance on the following treatments for melanoma. National Health Service commissioners are legally required to fund drugs and treatments recommended by NICE for eligible patients within three months of final guidance.</p><p> </p><table><tbody><tr><td><p>Appraisal number</p></td><td><p>Year of publication</p></td><td><p>Technology/condition</p></td><td><p>Recommendation</p></td></tr><tr><td><p>TA268</p></td><td><p>2012</p></td><td><p>Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA269</p></td><td><p>2012</p></td><td><p>Vemurafenib for locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA319</p></td><td><p>2014</p></td><td><p>Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA321</p></td><td><p>2014</p></td><td><p>Dabrafenib for unresectable or metastatic BRAF V600 mutation‑positive melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA357<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma after disease progression with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA366<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma not previously treated with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA384</p></td><td><p>2016</p></td><td><p>Nivolumab for advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA396</p></td><td><p>2016</p></td><td><p>Trametinib in combination with dabrafenib for unresectable or metastatic melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA400</p></td><td><p>2016</p></td><td><p>Nivolumab in combination with ipilimumab for advanced melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA410</p></td><td><p>2016</p></td><td><p>Talimogene laherparepvec for unresectable metastatic melanoma</p></td><td><p>Optimised recommendation for talimogene laherparepvec as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if: - treatment with systemically administered immunotherapies is not suitable; and - the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.</p></td></tr><tr><td><p>TA414</p></td><td><p>2016</p></td><td><p>Cobimetinib in combination with vemurafenib for unresectable or metastatic BRAF V600 mutation-positive melanoma</p></td><td><p>At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.</p></td></tr></tbody></table><p><sup>1</sup> pembrolizumab within its licensed indication was appraised across two separate appraisals.</p><p> </p><p>NHS England has advised that it has carefully translated the evidence base on which NICE has based its recommendations of clinical and cost effectiveness into practical clarifications which directly relate to how the recommended drug indication is incorporated into known treatment pathways in use in England.</p><p> </p><p>Each set of clarifications is in keeping with the NICE recommendations within the marketing authorisation of the relevant drug.</p><p> </p><p>The treatment criteria for both Cancer Drugs Fund and baseline-funded drug indications are set out in the National Cancer Drugs Fund List which is available at:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf</a></p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 57212 question first answered 20/12/2016 10:28:45 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4025 label Biography information for Mrs Pauline Latham

641291

	registered interest
	date	21/11/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to hold NHS England to account on the delivery of the diabetes metrics outlined in the Clinical Commissioning Group Improvement and Assessment Framework 2016-17.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	54082
	answer	answer is ministerial correction date of answer 28/11/2016 answer text <p>The mandate to NHS England requires it to develop the Clinical Commissioning Group Improvement and Assessment Framework (CCG IAF) and its supporting indicators in 2016-17, and in subsequent years to improve CCG performance against the indicators by 2020. This includes a specific reference to diabetes. NHS England is being held to account for achieving the deliverables in the 2016-17 mandate through regular assurance and accountability meetings with senior Departmental officials and my Rt. hon. Friend the Secretary of State. NHS England has completed the development of the framework and established baseline data for each group of indicators. In subsequent years, NHS England will be held to account for supporting CCGs to deliver improvements in the CCG IAF indicators.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 28/11/2016 15:22:27 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4025 label Biography information for Mrs Pauline Latham

641310

	registered interest
	date	21/11/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to support clinical commissioning groups that need improvement or have the greatest need for improvement for diabetes care under the Clinical Commissioning Group Improvement and Assessment Framework.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	53992
	answer	answer is ministerial correction date of answer 28/11/2016 answer text <p>NHS England will work with health communities/clinical commissioning groups (CCGs) in need of improvement against CCG Improvement and Assessment Framework indicators to mutually identify the nature of the change needed and the type of support required to achieve this. A key focus of improvement will be to support CCGs and providers to locally map their services against nationally recognised best practice diabetes pathways and to identify where local pathways need to change in order to improve outcomes. NHS England is developing plans for additional support to be available from 2017/18 onwards:</p><p> </p><p>- The NHS Operational Planning and Contracting Guidance 2017-2019 included an announcement that NHS England intends to launch a major programme of investment in the treatment and care of people with diabetes, for which CCGs will be able to bid for additional funding of approximately £40 million per year, focused on the key areas of diabetes care where improvements in outcomes will be most beneficial.</p><p> </p><p>- A Diabetes CCG Improvement and Assessment Framework Independent Panel has been developed, chaired by the Chief Executive of Diabetes UK and includes panel members with a wide range of other diabetes clinical expertise. This will consider CCG positions in relation to the diabetes Improvement and Assessment Framework indicators and advise on actions to support improvement.</p><p> </p><p>- Sustainability and Transformation Plans (STPs). As part of supporting the development of STPs, a “How to” guide for diabetes has been issued which sets out advice the actions which CCGs can take to support improvements.</p><p> </p><p>- NHS England regional teams: NHS England has funded diabetes programme leads within each of the National Health Service regions to work with CCGs to support improvement.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 28/11/2016 15:27:55 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4025 label Biography information for Mrs Pauline Latham

641311

	registered interest
	date	21/11/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Diabetes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what timetable he has set for publishing the next diabetes-specific ratings as part of the Clinical Commissioning Group Improvement and Assessment Framework; and if he will publish that data on a quarterly basis.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	53993
	answer	answer is ministerial correction date of answer 28/11/2016 answer text <p>As part of its statutory duty to perform an annual assessment of clinical commissioning groups (CCGs), NHS England will publish its 2016/17 annual assessment of the six clinical priority areas within the CCG Improvement and Assessment Framework in July 2017, which include diabetes. All indicators that are available are updated as frequently as possible; the diabetes indicators are based on annual data.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 28/11/2016 15:23:21 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4025 label Biography information for Mrs Pauline Latham

657133

	registered interest
	date	12/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Skin Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps are being taken to ensure melanoma patients have access to the most clinically effective treatment options if they have (a) brain metastases and (b) previously taken part in a clinical trial.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	57206
	answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) has recommended a number of drugs for use in the treatment of melanoma. National Health Service patients have a right in the NHS Constitution to drugs and treatments that have been recommended by NICE, where clinically appropriate.</p><p> </p><p>NHS England has advised that it has carefully translated the evidence base on which NICE has based its recommendations of clinical and cost effectiveness for drugs and treatments for melanoma into practical clarifications which directly relate to how the recommended drug indication is incorporated into known treatment pathways in use in England.</p><p> </p><p>Each set of clarifications is in keeping with the NICE recommendations within the marketing authorisation of the relevant drug.</p><p> </p><p>The treatment criteria for both Cancer Drugs Fund and baseline-funded drug indications are set out in the National Cancer Drugs Fund List which is available at:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf</a></p><p> </p><p>Discussions are taking place with NHS regional and National Cancer Research Institute experts on melanoma on formulating chemotherapy algorithms for the treatment of advanced or metastatic melanoma. These discussions relate in part to the drug treatment of brain metastases and the need to preserve recruitment to clinical trials and whether the qualifications that NHS England has applied in terms of treatment criteria for melanoma drugs within their respective marketing authorisations should be changed.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 20/12/2016 10:30:04 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4025 label Biography information for Mrs Pauline Latham

657164

	registered interest
	date	12/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Patients' Rights: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what his policy is on ensuring that patients have the right set out in the NHS Constitution to access any NICE-approved treatments that are clinically appropriate for them.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	57204
	answer	answer is ministerial correction date of answer 16/12/2016 answer text <p>National Health Service patients’ right in the NHS Constitution to drugs and treatments recommended in National Institute for Health and Care Excellence (NICE) technology appraisal and highly specialised technology guidance, where clinically appropriate, is underpinned by the legal requirement for NHS commissioners to fund such treatments, normally within three months of NICE issuing its final guidance.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 16/12/2016 12:11:23 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4025 label Biography information for Mrs Pauline Latham

657942

	registered interest
	date	13/12/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Derbyshire Healthcare NHS Foundation Trust: Disciplinary Proceedings
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many people have been suspended from the Derbyshire Mental Health Trust in the last two years; and for how long those suspensions were active.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	57293
	answer	answer is ministerial correction date of answer 19/12/2016 answer text <p>The information requested is not available centrally. It may be obtained from Derbyshire Healthcare NHS Foundation Trust. We have written to Richard Gregory, Chair of the Trust, informing him of the hon. Member’s enquiry. He will reply shortly and a copy of the letter will be placed in the Library.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 19/12/2016 15:17:15 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4025 label Biography information for Mrs Pauline Latham

688010

	registered interest
	date	09/02/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will take steps to increase the length of time that data is collected on the evaluation of treatment funded by the Cancer Drugs Fund.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	63820
	answer	answer is ministerial correction date of answer 20/02/2017 answer text <p>NHS England has advised that cancer drugs that are assessed by the National Institute for Health and Care Excellence (NICE) as having both key clinical uncertainties and plausible cost effectiveness can enter the Cancer Drugs Fund (CDF) for evaluation with a view to future NICE re-appraisal once there is sufficient data from continuing clinical trials and/or data collection in the CDF.</p><p> </p><p>The duration in the CDF for a cancer drug is determined on an individual basis by the time required for such data development/collection to take place. This will depend on the disease concerned, the data that needs to be examined, the clinical trials that may be already running, and considerations of cancer treatment pathways in England. The time that a drug stays in the CDF is therefore individually assessed and agreed with NHS England, NICE and the company concerned.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 20/02/2017 12:02:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4025 label Biography information for Mrs Pauline Latham

692584

	registered interest
	date	21/02/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 20 February 2017 to Question 63820, if he will take steps to increase the maximum length of time for which data can be collected on treatments funded from the Cancer Drugs Fund from two to three years.
	tabling member constituency	Mid Derbyshire
	tabling member printed	Pauline Latham
	uin	64926
	answer	answer is ministerial correction date of answer 01/03/2017 answer text <p>There is no maximum length of time for which data can be collected on treatments funded from the Cancer Drugs Fund (CDF). The duration in the CDF for a cancer drug is determined on an individual basis by the time required for such data development/collection to take place. This will depend on the disease concerned, the data that needs to be examined, the clinical trials that may be already running, and considerations of cancer treatment pathways in England. The time that a drug stays in the CDF is therefore individually assessed and agreed with NHS England, the National Institute for Health and Care Excellence and the company concerned. The timeframe will normally be up to two years, but will be considered on a case by case basis.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 01/03/2017 13:42:43 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4025 label Biography information for Mrs Pauline Latham